A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
← catalyst calendarNCT07205822 · readout in 531 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
40
Countries
China, France, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-30 | actual | When the study began enrolling |
| Primary completion | 2028-02-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-02 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Intervention
- Drug: Dato-DXd — also filed as IMP administration
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) per RECIST 1.1 as assessed by the investigator
measured From date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, whichever occurs first, assessed up to approximately 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed